Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Prescriptions Down at 41% of Medical Institutions due to COVID-19: Survey
November 5, 2020
- AstraZeneca Approached Us for Manufacturing of Coronavirus Vaccine Solution: JCR Exec
November 5, 2020
- Sosei, Aditum Bio Form New Firm to Develop Neurological Disease Drugs
November 4, 2020
- Astellas Now Aims at Peak Sales of 300-400 Billion Yen for Padcev with New Indications
November 4, 2020
- Shionogi/Tetra’s Cognitive Disorder Med Delivers Positive PII Data
November 4, 2020
- JCR Can Strike Global Licensing Deal for Lysosomal Therapies at Least by March-End: Chief
November 4, 2020
- Kyowa Kirin’s Overseas Sales Ratio Nears 50%, Driven by Crysvita in Europe, US: January-September
November 4, 2020
- Daiichi Sankyo Promoting Home Use of Inavir to Reduce COVID-19 Risk at Medical Institutions
November 4, 2020
- Shionogi Drops March-End Goal to Start Clinical Trials for COVID-19 Treatment
November 2, 2020
- Shionogi Sales Sag 9.3% in April-September on COVID-19, Price Cuts
November 2, 2020
- Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending
November 2, 2020
- Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
November 2, 2020
- European Regulators Accept Aducanumab for Review: Biogen/Eisai
November 2, 2020
- Ex-Merck Serono President Leo Lee Becomes Japan Chief of Novartis
November 2, 2020
- Lilly Pairs Up with Daiichi Sankyo to Commercialize Migraine Med Galcanezumab in Japan
November 2, 2020
- Daiichi Sankyo to Buyback 60 Million of Own Shares, Canceling 180 Million Treasury Shares
November 2, 2020
- Astellas Completes US iota Buyout to Shore Up Development of Implantable Medical Devices
November 2, 2020
- Takeda Done with Majority of Non-Core Asset Divestitures with US$10 Billion Target Achieved: CEO
October 30, 2020
- Takeda’s Half-Year Operating Profit Nearly Doubles on Drop in Costs, Shire Synergies
October 30, 2020
- Emerging from Repeated Price Cuts, Opdivo’s Japan Sales Could Top 100 Billion Yen in FY2020
October 30, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…